These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 16717252)
1. Issues in neuroprotection clinical trials in Parkinson's disease. Kieburtz K Neurology; 2006 May; 66(10 Suppl 4):S50-7. PubMed ID: 16717252 [TBL] [Abstract][Full Text] [Related]
2. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Hauser RA; Zesiewicz TA Neurology; 2006 May; 66(10 Suppl 4):S58-68. PubMed ID: 16717253 [TBL] [Abstract][Full Text] [Related]
3. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Olanow CW Neurology; 2006 May; 66(10 Suppl 4):S69-79. PubMed ID: 16717254 [TBL] [Abstract][Full Text] [Related]
4. Clinical trials with rasagiline: evidence for short-term and long-term effects. Siderowf A; Stern M Neurology; 2006 May; 66(10 Suppl 4):S80-8. PubMed ID: 16717255 [TBL] [Abstract][Full Text] [Related]
5. Neuroprotection in Parkinson's disease: myth or reality? Voss T; Ravina B Curr Neurol Neurosci Rep; 2008 Jul; 8(4):304-9. PubMed ID: 18590614 [TBL] [Abstract][Full Text] [Related]
6. A responsive outcome for Parkinson's disease neuroprotection futility studies. Elm JJ; Goetz CG; Ravina B; Shannon K; Wooten GF; Tanner CM; Palesch YY; Huang P; Guimaraes P; Kamp C; Tilley BC; Kieburtz K; Ann Neurol; 2005 Feb; 57(2):197-203. PubMed ID: 15668964 [TBL] [Abstract][Full Text] [Related]
7. Trial designs used to study neuroprotective therapy in Parkinson's disease. Lang AE; Melamed E; Poewe W; Rascol O Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotection in Parkinson's disease: an elusive goal. Biglan KM; Ravina B Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255 [TBL] [Abstract][Full Text] [Related]
9. The need for neuroprotective therapies in Parkinson's disease: a clinical perspective. Poewe W Neurology; 2006 May; 66(10 Suppl 4):S2-9. PubMed ID: 16717249 [TBL] [Abstract][Full Text] [Related]
10. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Clarke CE Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Hung AY; Schwarzschild MA Curr Opin Neurol; 2007 Aug; 20(4):477-83. PubMed ID: 17620885 [TBL] [Abstract][Full Text] [Related]
12. Designing neuroprotection trials in Parkinson's disease. Kieburtz K Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102 [TBL] [Abstract][Full Text] [Related]
16. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. Löhle M; Reichmann H J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974 [TBL] [Abstract][Full Text] [Related]
18. Clinical highlights. 17th International Symposium on ALS/MND Yokohama, Japan, November 30, 2006 through December 2, 2006. Mitsumoto H Amyotroph Lateral Scler; 2007 Apr; 8(2):119-20. PubMed ID: 17453641 [No Abstract] [Full Text] [Related]
19. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298 [TBL] [Abstract][Full Text] [Related]
20. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. Marras C; Lang AE Expert Rev Neurother; 2004 Nov; 4(6):985-93. PubMed ID: 15853525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]